CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Celularity Inc
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Oct 20, 2026
$1.16−0.09 (-7.20%)
Close on Oct 19, 2026
- Market cap
- $35.15M
- P/E (TTM)
- –
- Dividend yield
- –
Celularity Inc revenue by segment
By business segment
| Revenue | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Degenerative Disease [Member] | $9.66M | $17.31M | $31.86M | $37.62M | $44.75M | $48.39M | $42.96M | $37.32M | $28.15M | $17.33M | $9.28M | $9.65M | 50.9% | -78.4% |
| Biobanking [Member] | $5.27M | $5.43M | $5.41M | $5.26M | $5.26M | $5.14M | $5.24M | $5.37M | $5.37M | $5.44M | $5.51M | $5.49M | 27.8% | +0.2% |
| Cell Therapy [Member] | $4.04M | $3.81M | – | – | – | – | – | – | – | – | – | – | 21.3% | – |
By product or service
| Revenue | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License Royalty and Other [Member] | $8.67M | $7.94M | $13.74M | $15.41M | $14.19M | $13.74M | $7.25M | $3.31M | $3.20M | $4.18M | $4.81M | $5.83M | 45.7% | -38.9% |
| Service [Member] | $5.27M | $5.43M | $5.41M | $5.26M | $5.26M | $5.14M | $5.24M | $5.37M | $5.37M | $5.44M | $5.51M | $5.49M | 27.8% | +0.2% |
| Product [Member] | $5.02M | $13.18M | $21.43M | $23.93M | $31.51M | $35.34M | $35.72M | $34.01M | $24.95M | $13.15M | $4.46M | $3.82M | 26.5% | -84.1% |
By region
From the segment and revenue-disaggregation notes of Celularity's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.